These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24372611)

  • 1. Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease.
    Hopewell JC; Seedorf U; Farrall M; Parish S; Kyriakou T; Goel A; Hamsten A; Collins R; Watkins H; Clarke R;
    J Intern Med; 2014 Sep; 276(3):260-8. PubMed ID: 24372611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque.
    Ooi EM; Ellis KL; Barrett PHR; Watts GF; Hung J; Beilby JP; Thompson PL; Stobie P; McQuillan BM
    Atherosclerosis; 2018 Aug; 275():232-238. PubMed ID: 29960898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of serum lipoprotein(a) levels, apolipoprotein(a) size and (TTTTA)(n) polymorphism with coronary heart disease.
    Kalina A ; Császár A; Füst G; Nagy B; Szalai C; Karádi I; Duba J; Prohászka Z; Horváth L; Dieplinger H
    Clin Chim Acta; 2001 Jul; 309(1):45-51. PubMed ID: 11408005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Apolipoprotein(a) Isoform Size Using Phenotypic and Genotypic Methods.
    Fogacci F; Di Micoli V; Avagimyan A; Giovannini M; Imbalzano E; Cicero AFG
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease.
    Kraft HG; Lingenhel A; Köchl S; Hoppichler F; Kronenberg F; Abe A; Mühlberger V; Schönitzer D; Utermann G
    Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):713-9. PubMed ID: 8640397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors.
    Blanchard V; Chemello K; Hollstein T; Hong-Fong CC; Schumann F; Grenkowitz T; Nativel B; Coassin S; Croyal M; Kassner U; Lamina C; Steinhagen-Thiessen E; Lambert G
    Cardiovasc Res; 2022 Jul; 118(9):2103-2111. PubMed ID: 34314498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.
    Chan DC; Watts GF; Coll B; Wasserman SM; Marcovina SM; Barrett PHR
    J Am Heart Assoc; 2019 Apr; 8(7):e011781. PubMed ID: 30897995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different apoprotein(a) isoform proportions in serum and carotid plaque.
    Baldo G; Giunco S; Kontothanassis D; Baiocchi MR; Valerio A; Frego M
    Atherosclerosis; 2007 Jul; 193(1):177-85. PubMed ID: 16839560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of apolipoprotein(a) isoform size with clearance and production of lipoprotein(a) in a diverse cohort.
    Matveyenko A; Matienzo N; Ginsberg H; Nandakumar R; Seid H; Ramakrishnan R; Holleran S; Thomas T; Reyes-Soffer G
    J Lipid Res; 2023 Mar; 64(3):100336. PubMed ID: 36706955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension.
    Gazzaruso C; Buscaglia P; Garzaniti A; Falcone C; Mariotti S; Savino S; Bonetti G; Finardi G; Geroldi D
    J Hypertens; 1997 Mar; 15(3):227-35. PubMed ID: 9468449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults.
    Beheshtian A; Shitole SG; Segal AZ; Leifer D; Tracy RP; Rader DJ; Devereux RB; Kizer JR
    Atherosclerosis; 2016 Oct; 253():47-53. PubMed ID: 27575936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study.
    Parish S; Hopewell JC; Hill MR; Marcovina S; Valdes-Marquez E; Haynes R; Offer A; Pedersen TR; Baigent C; Collins R; Landray M; Armitage J;
    Circ Genom Precis Med; 2018 Feb; 11(2):e001696. PubMed ID: 29449329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis.
    Saleheen D; Haycock PC; Zhao W; Rasheed A; Taleb A; Imran A; Abbas S; Majeed F; Akhtar S; Qamar N; Zaman KS; Yaqoob Z; Saghir T; Rizvi SNH; Memon A; Mallick NH; Ishaq M; Rasheed SZ; Memon FU; Mahmood K; Ahmed N; Frossard P; Tsimikas S; Witztum JL; Marcovina S; Sandhu M; Rader DJ; Danesh J
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):524-533. PubMed ID: 28408323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein(a) size polymorphism is associated with coronary heart disease in polygenic hypercholesterolemia.
    Emanuele E; Peros E; Minoretti P; D'Angelo A; Piccinni MN; Montagna L; Geroldi D
    Nutr Metab Cardiovasc Dis; 2004 Aug; 14(4):193-9. PubMed ID: 15553596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterozygous apolipoprotein (a) status and protein expression as a risk factor for premature coronary heart disease.
    Martín S; Pedro-Botet J; Joven J; Simó JM; Ladona MG; Pavesi M; Rubiés-Prat J
    J Lab Clin Med; 2002 Mar; 139(3):181-7. PubMed ID: 11944029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum lipoprotein(a) concentrations and apolipoprotein(a) isoforms: association with the severity of clinical presentation in patients with coronary heart disease.
    Katsouras CS; Karabina SA; Tambaki AP; Goudevenos JA; Michalis LK; Tsironis LD; Stroumbis CS; Elisaf MS; Sideris DA; Tselepis AD
    J Cardiovasc Risk; 2001 Oct; 8(5):311-7. PubMed ID: 11702038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size.
    Tsimikas S; Fazio S; Viney NJ; Xia S; Witztum JL; Marcovina SM
    J Clin Lipidol; 2018; 12(5):1313-1323. PubMed ID: 30100157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study.
    Lamon-Fava S; Marcovina SM; Albers JJ; Kennedy H; DeLuca C; White CC; Cupples LA; McNamara JR; Seman LJ; Bongard V; Schaefer EJ
    J Lipid Res; 2011 Jun; 52(6):1181-1187. PubMed ID: 21478162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants.
    Erqou S; Thompson A; Di Angelantonio E; Saleheen D; Kaptoge S; Marcovina S; Danesh J
    J Am Coll Cardiol; 2010 May; 55(19):2160-7. PubMed ID: 20447543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant differentiation in the apolipoprotein(a)/lipoprotein(a) trait between chimpanzees from Western and Central Africa.
    Noureen A; Ronke C; Khalifa M; Halbwax M; Fischer A; André C; Atencia R; Garriga R; Mugisha L; Ceglarek U; Thiery J; Utermann G; Schmidt K
    Am J Primatol; 2017 Sep; 79(9):. PubMed ID: 28671714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.